Sodium–glucose cotransporter 2 inhibitor‐associated diabetic ketoacidosis in patients with type 1 diabetes: Metabolic imbalance as an underlying mechanism

Sodium–glucose cotransporter 2 inhibitor‐associated diabetic ketoacidosis in patients with type 1 diabetes: Metabolic imbalance as an underlying mechanism

Bibliographic Details
Main Authors:	Wataru Ogawa, Yushi Hirota
Format:	Article
Language:	English
Published:	Wiley 2019-07-01
Series:	Journal of Diabetes Investigation
Online Access:	https://doi.org/10.1111/jdi.13026

Similar Items

Balancing Risks and Benefits: Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis
by: Jan P. Kleinjan, et al.
Published: (2024-03-01)

Inhibitors of sodium-glucose cotransporter 2: risk of ketoacidosis
by: T. M. Bukatina, et al.
Published: (2018-02-01)

Sodium-glucose Cotransporter-2 Induced Diabetic Ketoacidosis with Minimal Hyperglycemia
by: D. Taylor Gammons
Published: (2018-01-01)

On‐label use of sodium–glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes
by: Takeshi Horii, et al.
Published: (2021-09-01)

Diabetic Ketoacidosis Associated with Sodium-Glucose Cotransporter 2 Inhibitors: Clinical and Biochemical Characteristics of 29 Cases
by: G. A. Stamatiades, et al.
Published: (2023-01-01)

Metabolic ketoacidosis with normal blood glucose: A rare complication of sodium–glucose cotransporter 2 inhibitors
by: Saad Ullah, et al.
Published: (2016-11-01)

Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin
by: Daniel A. Kelmenson MD, et al.
Published: (2017-06-01)

Sodium–glucose cotransporter 2 inhibitor‐induced euglycaemic diabetic ketoacidosis in heart failure with preserved ejection fraction
by: Luka Cavka, et al.
Published: (2021-08-01)

Risk of Diabetic Ketoacidosis Associated with Sodium Glucose Cotransporter-2 Inhibitors: A Network Meta-Analysis and Meta-Regression
by: Kannan Sridharan, et al.
Published: (2024-03-01)

Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature
by: Alexis Diaz-Ramos, et al.
Published: (2019-09-01)

A case of sodium-glucose cotransporter-2 inhibitor-associated euglycemic diabetic ketoacidosis complicated by concurrent subacute thyroiditis
by: Miyu Kinoshita, et al.
Published: (2022-09-01)

Sodium–glucose cotransporter‐2 inhibitors induced euglycemic diabetic ketoacidosis: Two case reports and a review of the literature
by: Zouheir Ibrahim Bitar, et al.
Published: (2022-02-01)

An atypical hyperosmolar hyperglycemic state and diabetic ketoacidosis induced by sodium–glucose cotransporter-2 inhibitors: A case report
by: Chen-Ti Wang, et al.
Published: (2020-08-01)

Euglycemic diabetic ketoacidosis development in a patient with type 2 diabetes receiving a sodium-glucose cotransporter-2 inhibitor and a carbohydrate-restricted diet
by: Gwanpyo Koh, et al.
Published: (2023-09-01)

Euglycemic diabetic ketoacidosis associated with sodium–glucose cotransporter-2 inhibitors after surgery: A case report and review of literature
by: Mei-An Pai, et al.
Published: (2023-01-01)

A Case of STEMI-Induced Euglycemic Diabetic Ketoacidosis in a Patient Receiving a Sodium Glucose Cotransporter-2 Inhibitor
by: Marc Zughaib, DO, et al.
Published: (2023-04-01)

Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus
by: Ahmadieh H, et al.
Published: (2017-05-01)

Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
by: Giovanni Musso, et al.
Published: (2020-12-01)

Sodium–Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes
by: Muhammad Shahzeb Khan, et al.
Published: (2019-11-01)

Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes
by: Kim Y, et al.
Published: (2012-08-01)

Safety of sodium–glucose cotransporter 2 inhibitors in Asian type 2 diabetes populations
by: Jaime A Davidson, et al.
Published: (2023-02-01)

Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives
by: Mathew John, et al.
Published: (2016-01-01)

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
by: M. Arow, et al.
Published: (2020-01-01)

Does Treatment with Sodium-Glucose Cotransporter-2 Inhibitors Affect Adherence to International Society Criteria for Diabetic Ketoacidosis in Adult Patients with Type 2 Diabetes? A Retrospective Cohort Analysis
by: Aongus O’Brolchain, et al.
Published: (2024-01-01)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
by: Jun Tang, et al.
Published: (2022-02-01)

The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management
by: Bo Xu, et al.
Published: (2022-05-01)

Erratum: Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives
Published: (2016-01-01)

Sodium-Glucose Transport Protein 2 Inhibitors Association with Euglycemic Diabetic Ketoacidosis
by: Caroline Wojtas, et al.
Published: (2023-01-01)

Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients
by: Boyang Xiang, et al.
Published: (2021-04-01)

Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes
by: Koki Chiba, et al.
Published: (2021-02-01)

Sodium-glucose cotransporter-2 inhibitors induced eu-glycemic diabetic ketoacidosis: The first report in a type 2 diabetic (T2D) Taiwanese and literature review of possible pathophysiology and contributing factors
by: Yi-Hsin Lin
Published: (2018-09-01)

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
by: Vasilakou, D, et al.
Published: (2013)

Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians
by: Muhammad Afzal, et al.
Published: (2021-11-01)

The Mechanism of Sodium-Glucose Cotransporter-2 Inhibitors in Reducing Uric Acid in Type 2 Diabetes Mellitus
by: Dong M, et al.
Published: (2023-02-01)

Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes
by: Navya Varshney, et al.
Published: (2021-03-01)

Sodium-glucose cotransporter-2 inhibitors in combination with other glucose-lowering agents for the treatment of type 2 diabetes mellitus
by: Sanjay Kalra, et al.
Published: (2018-01-01)

Sodium‐Glucose Cotransporter‐2 Inhibitor Prevents Stroke in Patients With Diabetes and Atrial Fibrillation
by: Sheng‐Nan Chang, et al.
Published: (2023-05-01)

Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition
by: Resham Raj Poudel
Published: (2013-01-01)

Euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus 3 days after initiating sodium‐glucose cotransporter 2 inhibitor while on an extremely low carbohydrate diet: A case report
by: Ayumi Inoue, et al.
Published: (2022-11-01)

Serum glucose, sodium and potassium concentrations in patients with diabetic ketoacidosis
by: Željka Dragila, et al.
Published: (2022-08-01)